Sung C C, Pearl D K, Coons S W, Scheithauer B W, Johnson P C, Zheng M, Yates A J
Division of Neuropathology, Ohio State University, Columbus.
Cancer. 1995 Feb 1;75(3):851-9. doi: 10.1002/1097-0142(19950201)75:3<851::aid-cncr2820750317>3.0.co;2-h.
Classification/grading schemes for brain tumors are based mainly on histologic examinations, but these have major limitations, which has led to a search for more objective prognostic markers. Gangliosides have several biologic effects relevant to tumors, and ganglioside compositions of primary brain tumors correlate with diagnosis. This led to the authors' hypothesis that ganglioside patterns of brain tumors might be useful as prognostic indicators.
Gangliosides in primary brain tumors of different histologic types from 84 patients were analyzed. Specific ganglioside patterns and several other relevant variables were examined for associations with survival using a Cox proportional hazards model. Kaplan-Meier survival curves were analyzed using the log-rank test.
Patients in whom less than 30% of total tumor gangliosides consisted of 1b pathway gangliosides (GD1b, GT1b, and GQ1b) had significantly higher risk ratios than those with more than 30% 1b gangliosides (P approximately 0.03). The presence of 6'-LM1 (NeuAc alpha 2-->6Gal beta 1-->4Glc-NAc beta 1-->3Gal beta 1-->4Glc beta 1-->1Cer was also associated with a higher risk ratio (P approximately 0.007). Combinations of 1b gangliosides and 6'-LM1 identified three groups of patients regardless of histologic diagnosis. Group A, with less than 30% 1b and the presence of 6'-LM1, had a median survival time of 331 days. Group B, with less than 30% 1b but no 6'-LM1, had a median survival time of more than 698 days. Group C, with more than 30% 1b had a median survival time of more than 776 days.
The correlation of ganglioside patterns with survival in this initial investigation suggests the potential of 1b gangliosides and 6'-LM1 to be used as prognostic indicators. Continuing research is being conducted to assess this possibility prospectively.
脑肿瘤的分类/分级方案主要基于组织学检查,但这些检查有很大局限性,这促使人们寻找更客观的预后标志物。神经节苷脂具有多种与肿瘤相关的生物学效应,原发性脑肿瘤的神经节苷脂组成与诊断相关。这使得作者提出假说,即脑肿瘤的神经节苷脂模式可能作为预后指标。
分析了84例不同组织学类型原发性脑肿瘤中的神经节苷脂。使用Cox比例风险模型检查特定神经节苷脂模式和其他几个相关变量与生存的关联。使用对数秩检验分析Kaplan-Meier生存曲线。
肿瘤总神经节苷脂中少于30%由1b途径神经节苷脂(GD1b、GT1b和GQ1b)组成的患者,其风险比显著高于1b神经节苷脂超过30%的患者(P约为0.03)。6'-LM1(NeuAcα2→6Galβ1→4Glc-NAcβ1→3Galβ1→4Glcβ1→1Cer)的存在也与较高的风险比相关(P约为0.007)。无论组织学诊断如何,1b神经节苷脂和6'-LM1的组合确定了三组患者。A组,1b少于30%且存在6'-LM1,中位生存时间为331天。B组,1b少于30%但无6'-LM1,中位生存时间超过698天。C组,1b超过30%,中位生存时间超过776天。
在这项初步研究中,神经节苷脂模式与生存的相关性表明1b神经节苷脂和6'-LM1有可能用作预后指标。正在进行持续研究以前瞻性地评估这种可能性。